Results 101 to 110 of about 28,144 (206)

Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence, Risk Factors at a Tertiary Care Hospital in Nepal: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Epistaxis is a common complication associated with oral anticoagulant and antiplatelet therapies, often leading to significant morbidity. In recent years, the incidence of cardiovascular disease in Nepal has risen dramatically, driving a widespread use of these medications and heightened concerns regarding bleeding ...
Shiv Kumar Sah, Ashok Kumar Gupta, Sanjaya Acharya, Suraj Kumar Thakur, Rajkumar Chaudhary, Shiva Pandeya, Arjun Budthapa, Vijaya K. C., Sajish Khadgi, Manjita Bajracharya   +9 more
wiley   +1 more source

From Negative Duplex to Phlegmasia in Minutes: Bedside POCUS Identifies Rapid Thrombosis Unmasking Underlying May–Thurner Syndrome

Journal of Clinical Ultrasound, Volume 54, Issue 7, Page 1799-1803, September 2026.
Point‐of‐care‐ultrasound revealed an evolving acute noncompressible deep vein thrombosis (asterisks) in the left lower extremity veins (right panel) that was not evident on duplex ultrasound 14 min prior (left panel; asterisks demonstrate compressed veins). The patient was treated emergently and found to have May–Thurner syndrome.
Anthony Unger
wiley   +1 more source

Reduced postoperative inflammation and blood loss after robotic arm‐assisted unicompartmental compared with total knee arthroplasty: A propensity score‐matched analysis

Knee Surgery, Sports Traumatology, Arthroscopy, Volume 34, Issue 9, Page 3339-3347, September 2026.
Abstract Purpose Robotic arm‐assisted unicompartmental knee arthroplasty (raUKA) offers potential advantages over robotic arm‐assisted total knee arthroplasty (raTKA), but its biological benefits remain unclear. Superior early recovery after raUKA may be related to reduced systemic inflammation and blood loss.
Dirk Müller, Florian Pohlig, Benjamin Schloßmacher, Vincent Lallinger, Michael T. Hirschmann, Rüdiger von Eisenhart‐Rothe, Igor Lazic   +6 more
wiley   +1 more source

Apixaban and clopidogrel in a fixed-dose combination: Formulation and in vitro evaluation

Saudi Pharmaceutical Journal
Fixed-dose combination (FDC) products represent a novel, safe, and cost-effective formulation. Combined use of anticoagulant and antiplatelet medications is common among comorbid cardiovascular patients.
Ni'meh Al-Shami, Hani Naseef, Feras Kanaze   +2 more
doaj   +1 more source

Neurocardiology: Brain–Heart Interactions in the Heart

MedComm, Volume 7, Issue 9, September 2026.
The heart and brain maintain systemic homeostasis through bidirectional communication involving neural, biochemical, and mechanical pathways. Dysregulation of these pathways contributes to a spectrum of conditions involving heart–brain interactions, including Takotsubo syndrome, the epileptic heart, stroke–heart syndrome, heart failure, cardiac ...
Wentao Wang, Hao Jia, Han Han, Jiangping Song   +3 more
wiley   +1 more source

Therapeutic Drug Monitoring of Apixaban Using Chromogenic Kits [PDF]

, 2020
Apixaban is a novel oral anticoagulant that prevents clotting by directly inhibiting Factor Xa in the coagulation cascade. Due to its different pharmacokinetics, previous standards for testing anticoagulant concentrations are ineffective at measuring ...
Vogel, Brooke
core   +1 more source

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World

American Journal of Hematology, Volume 101, Issue 9, Page 2463-2468, September 2026.
Rodrigo Ortega Perez, Luis Manuel Domínguez Rodríguez, Francisca Ferrer‐Marín, Beatriz Cuevas Ruíz, Clara Martínez Valverde, Patricia Vélez Tenza, María Isabel Mata Vázquez, Adrián Segura Díaz, María Laura Fox, Elvira Mora, Manuel Mateo Pérez Encinas, Mercedes Gasior Kabat, Gonzalo Carreño‐Tarragona, Rafael Andrés del Orbe, Gonzalo Caballero‐Navarro, Elena Magro Mazo, Ana Pardo Sanz, José Luis Zamorano Gómez, Alberto Álvarez Larrán, Valentín Garcia‐Gutierrez   +19 more
wiley   +1 more source

Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 9, September 2026.
The clinical manifestations of PFO. Although the majority of PFOs are benign and asymptomatic, they can present with a variety of clinical manifestations, or coexisting with other diseases and aggravating their symptoms, including cerebral diseases (such as CS, epilepsy, TIA, or migraine), systemic embolism (such as embolism in renal artery, coronary ...
Linlin Meng, Xiaotong Zhang, Guangrui Sun, Honggang Dai, Xiao Meng, Cheng Zhang, Yun Zhang   +6 more
wiley   +1 more source

Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990–2021)

Neuroprotection, Volume 4, Issue 3, Page 199-212, September 2026.
Epilepsy: Global Trends and the Chinese Experience (1990–2021). The infographic depicts (left) the global distribution of age‐standardized epilepsy DALY rates; (center) the triple inequality gap within China, including regional mortality disparities (9‐fold difference between western and eastern provinces), urban‐rural treatment gaps (60%–90%), and ...
Ting Chen, Mengqiao He, Sijia Basang, Hongyu Ren, Yutong Fu, Yu Li, Xin Shi, Lei Chen   +7 more
wiley   +1 more source

Apixaban for extended treatment of venous thromboembolism.

, 2013
Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. Methods In this randomized, double-blind study, we compared two doses of
PALLA, ANTONIO, Cohen A, Group Author: AMPLIFY EXT Investigators, Buller HR, Gallus AS, Johnson M, Agnelli G, Curto M, Raskob GE, Weitz JI, Porcari A   +10 more
core